Oncology
EMD Serono, Inc. is growing its presence in oncology in the U.S, with a focus on developing novel first-in-class therapies
targeting the cancer disease process. EMD Serono aspires to develop products that provide beneficial therapeutic outcomes
and create new options for cancer patients.
EMD Serono focuses on developing potentially novel, first-in-class investigational therapies for oncology that focus on three
underlying areas: tumor cell, the tumor environment and immune system.
Combination is key for EMD Serono:
Developing products that target multiple aspects of the cancer disease process and are suitable for use in combination with
established therapies.
Combining innovative thinking with intelligent research and technical excellence.
We have brought together a dedicated group of individuals who can look beyond conventional horizons. They have the experience and motivation required to identify first-in-class targets and develop novel cancer treatment strategies.
We have brought together a dedicated group of individuals who can look beyond conventional horizons. They have the experience and motivation required to identify first-in-class targets and develop novel cancer treatment strategies.
Combining insights, experience and skills.
We are committed to working in partnership with oncology experts, patients, and healthcare providers, striving to meet the needs of patients for better medicines, and to improve access to these medicines by collaborative teamwork and sharing of skills. Moreover, this strategy combines the areas of radiotherapy, surgery, and medical treatments to create a multidisciplinary approach for the benefit of cancer patients everywhere.
We are committed to working in partnership with oncology experts, patients, and healthcare providers, striving to meet the needs of patients for better medicines, and to improve access to these medicines by collaborative teamwork and sharing of skills. Moreover, this strategy combines the areas of radiotherapy, surgery, and medical treatments to create a multidisciplinary approach for the benefit of cancer patients everywhere.
We focus our work in oncology on developing novel first-in-class investigational therapies designed to target the cancer process.
